Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)
NCT: NCT06378528 · SUSPENDED
Brief Summary
The objectives of this study are to investigate the feasibility, tolerability, and preliminary efficacy of repeated ketamine-assisted psychotherapy sessions in adolescents with severe posttraumatic stress disorder. The study will enroll adolescents with a current diagnosis of posttraumatic stress disorder (PTSD) to complete three intravenous ketamine administrations accompanied by a psychotherapy session over the span of six weeks. All participants will complete an initial set of preparatory sessions, and each dosing session will be followed by three to six hours of integration sessions. Finally, participants will complete 7 nights of at-home sleep recordings. The investigators hypothesize that this protocol will be well-tolerated by adolescents and that patients will experience decreases in PTSD symptom severity at follow-up.
Frequently Asked Questions
What is Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)?
Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) is a clinical trial registered under NCT06378528. Current status: SUSPENDED.
What is the status of NCT06378528?
The current status of NCT06378528 (Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)) is: SUSPENDED.
When did Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) start?
Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) started on 2026-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.